• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

免疫检查点抑制剂诱发糖尿病发病前后胰岛素分泌能力的纵向观察：两例报告

Longitudinal observation of insulin secretory ability before and after the onset of immune checkpoint inhibitor-induced diabetes mellitus: A report of two cases.

作者信息

Fujiwara Noriko, Watanabe Mayu, Katayama Akihiro, Noda Yohei, Eguchi Jun, Kataoka Hitomi, Kagawa Shunsuke, Wada Jun

机构信息

Department of Nephrology, Rheumatology, Endocrinology and Metabolism Dentistry and Pharmaceutical Sciences Okayama University Graduate School of Medicine Okayama Japan.

Division of Endocrinology and Metabolism Hiroshima Red Cross Hospital and Atomic-bomb Survivors Hospital Hiroshima Japan.

出版信息

Clin Case Rep. 2021 Sep 7;9(9):e04574. doi: 10.1002/ccr3.4574. eCollection 2021 Sep.

DOI:10.1002/ccr3.4574
PMID:34522382
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8424178/
Abstract

Immune checkpoint inhibitor-induced diabetes mellitus is a rare immune-related adverse event. This report illustrates clinical data and insulin secretory ability before and after the onset of immune checkpoint inhibitor-induced diabetes.

摘要

免疫检查点抑制剂诱导的糖尿病是一种罕见的免疫相关不良事件。本报告阐述了免疫检查点抑制剂诱导的糖尿病发病前后的临床数据及胰岛素分泌能力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b41c/8424178/1d2a024010ed/CCR3-9-e04574-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b41c/8424178/1d2a024010ed/CCR3-9-e04574-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b41c/8424178/1d2a024010ed/CCR3-9-e04574-g002.jpg

相似文献

1
Longitudinal observation of insulin secretory ability before and after the onset of immune checkpoint inhibitor-induced diabetes mellitus: A report of two cases.免疫检查点抑制剂诱发糖尿病发病前后胰岛素分泌能力的纵向观察：两例报告
Clin Case Rep. 2021 Sep 7;9(9):e04574. doi: 10.1002/ccr3.4574. eCollection 2021 Sep.
2
Rare, late onset of immune checkpoint inhibitor-induced type 1 diabetes mellitus in a patient with small-cell lung cancer treated with serplulimab: a case report and review of the literature.免疫检查点抑制剂诱发的 1 型糖尿病：赛普利单抗治疗小细胞肺癌 1 例并文献复习
J Med Case Rep. 2024 Jan 22;18(1):51. doi: 10.1186/s13256-023-04248-7.
3
Recovery from insulin dependence in immune checkpoint inhibitor-associated diabetes mellitus: A case report.免疫检查点抑制剂相关糖尿病中胰岛素依赖的恢复：病例报告。
J Diabetes Investig. 2023 Jan;14(1):147-150. doi: 10.1111/jdi.13927. Epub 2022 Oct 17.
4
Clinical outcomes of immune checkpoint inhibitor diabetes mellitus at a comprehensive cancer center.综合性癌症中心免疫检查点抑制剂糖尿病的临床结局。
Immunotherapy. 2023 Apr;15(6):417-428. doi: 10.2217/imt-2021-0316. Epub 2023 Apr 4.
5
Clinical characteristics and outcomes of immune checkpoint inhibitor-induced diabetes mellitus.免疫检查点抑制剂诱发糖尿病的临床特征及结局
Transl Oncol. 2022 Oct;24:101473. doi: 10.1016/j.tranon.2022.101473. Epub 2022 Jul 26.
6
[Immune Checkpoint Inhibitors Related Diabetes Mellitus: 
A Report of 2 Cases and Literature Review].[免疫检查点抑制剂相关糖尿病：2例报告及文献复习]
Zhongguo Fei Ai Za Zhi. 2022 Jan 20;25(1):61-65. doi: 10.3779/j.issn.1009-3419.2021.102.54.
7
Immune checkpoint inhibitor-induced diabetes mellitus with pembrolizumab.免疫检查点抑制剂相关的糖尿病，与派姆单抗相关。
BMJ Case Rep. 2022 Jan 17;15(1):e245846. doi: 10.1136/bcr-2021-245846.
8
A single center case series of immune checkpoint inhibitor-induced type 1 diabetes mellitus, patterns of disease onset and long-term clinical outcome.免疫检查点抑制剂诱导的 1 型糖尿病的单中心病例系列，疾病发作模式和长期临床结局。
Front Immunol. 2023 Aug 21;14:1229823. doi: 10.3389/fimmu.2023.1229823. eCollection 2023.
9
Immune checkpoint inhibitor diabetes mellitus: a novel form of autoimmune diabetes.免疫检查点抑制剂相关性糖尿病：一种新型自身免疫性糖尿病。
Clin Exp Immunol. 2020 May;200(2):131-140. doi: 10.1111/cei.13424. Epub 2020 Feb 28.
10
Case of slowly progressive type 1 diabetes mellitus with drastically reduced insulin secretory capacity after immune checkpoint inhibitor treatment for advanced renal cell carcinoma.晚期肾细胞癌免疫检查点抑制剂治疗后出现胰岛素分泌能力大幅下降的缓慢进展型1型糖尿病病例。
Diabetol Int. 2020 Aug 24;12(2):234-240. doi: 10.1007/s13340-020-00459-1. eCollection 2021 Apr.

引用本文的文献

1
Flash Glucose Monitoring and Diabetes Mellitus Induced by Immune Checkpoint Inhibitors: An Approach to Clinical Practice.实时动态血糖监测与免疫检查点抑制剂所致糖尿病：临床实践方法探讨。
J Diabetes Res. 2022 Nov 4;2022:4508633. doi: 10.1155/2022/4508633. eCollection 2022.

本文引用的文献

1
Sintilimab-Induced Autoimmune Diabetes in a Patient With the Anti-tumor Effect of Partial Regression.信迪利单抗诱导的自身免疫性糖尿病在一名具有部分缓解抗肿瘤效应的患者中发生。
Front Immunol. 2020 Aug 21;11:2076. doi: 10.3389/fimmu.2020.02076. eCollection 2020.
2
Anti PD-1 monoclonal antibody induced autoimmune diabetes mellitus: a case report and brief review.抗程序性死亡蛋白1单克隆抗体诱发自身免疫性糖尿病：一例报告及简要综述
Transl Lung Cancer Res. 2020 Apr;9(2):379-388. doi: 10.21037/tlcr.2020.03.05.
3
Immune Checkpoint Inhibitor-Induced Diabetic Ketoacidosis: A Report of Four Cases and Literature Review.
免疫检查点抑制剂相关糖尿病酮症酸中毒：四例报告及文献复习。
Front Endocrinol (Lausanne). 2020 Jan 28;11:14. doi: 10.3389/fendo.2020.00014. eCollection 2020.
4
Immune checkpoint inhibitor diabetes mellitus: a novel form of autoimmune diabetes.免疫检查点抑制剂相关性糖尿病：一种新型自身免疫性糖尿病。
Clin Exp Immunol. 2020 May;200(2):131-140. doi: 10.1111/cei.13424. Epub 2020 Feb 28.
5
Combined immune checkpoint inhibitor therapy with nivolumab and ipilimumab causing acute-onset type 1 diabetes mellitus following a single administration: two case reports.纳武利尤单抗和伊匹单抗联合免疫检查点抑制剂治疗导致单次给药后急性发作 1 型糖尿病：两例报告。
BMC Endocr Disord. 2019 Dec 23;19(1):144. doi: 10.1186/s12902-019-0467-z.
6
Checkpoint Inhibitor-Associated Autoimmune Diabetes Is Distinct From Type 1 Diabetes.免疫检查点抑制剂相关自身免疫性糖尿病与 1 型糖尿病不同。
J Clin Endocrinol Metab. 2019 Nov 1;104(11):5499-5506. doi: 10.1210/jc.2019-00423.
7
A Patient with Nivolumab-related Fulminant Type 1 Diabetes Mellitus whose Serum C-peptide Level Was Preserved at the Initial Detection of Hyperglycemia.一名患有与纳武单抗相关的暴发性1型糖尿病的患者，其血清C肽水平在高血糖初次检测时保持正常。
Intern Med. 2019 Oct 1;58(19):2825-2830. doi: 10.2169/internalmedicine.2780-19. Epub 2019 Jun 27.
8
Fulminant type 1 diabetes mellitus induced by pembrolizumab in a patient with urothelial carcinoma: A case report.派姆单抗诱发的1型暴发性糖尿病在一名尿路上皮癌患者中的病例报告
Urol Case Rep. 2019 Feb 15;24:100849. doi: 10.1016/j.eucr.2019.100849. eCollection 2019 May.
9
Immune checkpoint inhibitor-induced Type 1 diabetes: a systematic review and meta-analysis.免疫检查点抑制剂相关 1 型糖尿病：系统评价和荟萃分析。
Diabet Med. 2019 Sep;36(9):1075-1081. doi: 10.1111/dme.14050. Epub 2019 Jul 7.
10
Nivolumab-induced type 1 diabetes mellitus as an immune-related adverse event.纳武利尤单抗诱导的1型糖尿病作为一种免疫相关不良事件。
J Oncol Pharm Pract. 2020 Jan;26(1):236-239. doi: 10.1177/1078155219841116. Epub 2019 Apr 7.